# Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect

> **NCT03116893** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 685509 After Standardised Breakfast
- **DRUG:** Itraconazole
- **DRUG:** Rifampin
- **DRUG:** BI 685509 Fasted Conditions

## Key facts

- **NCT ID:** NCT03116893
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-19
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116893, "Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03116893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*